Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135403 | 1.00 | LTA4H (0.51) | LTA4HSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL27755643 | 0.83 | BCHE (0.44) | SLC6A2SLC6A3SIGMAR1HRH3 | |
| SCHEMBL4048093 | 0.81 | SIGMAR1 (0.42) | SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL4048099 | 0.81 | SIGMAR1 (0.42) | SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL4130475 | 0.80 | ALDH1A1 (0.55) | — | |
| SCHEMBL4130478 | 0.80 | ALDH1A1 (0.55) | — | |
| SCHEMBL27735104 | 0.77 | ALDH1A1 (0.38) | SLC6A2SLC6A4SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL25377090 | 0.76 | LTA4H (0.62) | LTA4HSIGMAR1HRH3 | |
| SCHEMBL3888376 | 0.76 | HRH3 (0.63) | LTA4HSIGMAR1HRH3 | |
| SCHEMBL27735105 | 0.76 | CYP3A4 (0.36) | SLC6A2SLC6A4SLC6A3SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | LTA4H 470/4885SLC6A2 941/4885SLC6A4 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.